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disease data. In the absence of comparative clinical evidence, Duodopa and 
Apomorphine were assumed to have equivalent efficacy to DBS. The cost analysis 
covered: device acquisition, implantation, adverse event management, concomitant 
drug use, device replacements and follow-up. Cost data were taken from Swedish 
tariffs, drug list prices and device prices. Costs and QALYs were both discounted 
at 3% per year. Results: The incremental cost-effectiveness ratio for DBS versus 
BMT was SEK 387,313 per QALY gained, using a time horizon of 15 years. DBS was 
predicted to be cost-saving versus Duodopa at 5 years (with a saving of SEK 534,000 
per patient) and at 10 years versus Apomorphine. The key parameters in the model 
were the costs of the DBS device components and the unit costs of the advanced 
drug therapies. ConClusions: The results suggest that DBS is a cost-effective 
intervention compared with BMT, based on the informal threshold used in Sweden 
(SEK 500,000 per QALY gained). When compared against Apomorphine and Duodopa, 
the high initial costs of DBS equipment and implantation are offset in the long-term 
by reduced medication costs.
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objeCtives: It is estimated that that approximately 10-30% of all women worldwide 
are affected by menorrhagia once in their life time. Several endometrial ablation 
techniques can be chosen in order to preserve the uterus while stopping or reduc-
ing uterine bleeding. Evidence reports that radiofrequency ablation (RFA) is easier 
and faster to apply and hence result in cost savings compared to other ablation 
devices. Methods: A sex- and age adjusted database of > 4 million insured were 
analysed (≈5% of the German SHI population). 32,246 patients suffering from men-
orrhagia were identified. These cases were further investigated for the application 
of RFA (intervention group) or other endometrial ablation techniques (rollerball/ 
loop resection/ balloon thermal ablation (control group)). Propensity score matching 
(PSM) was used to make both study groups appropriately comparable. Patients were 
observed for a follow-up period of 2 years. Results: After performing PSM, 50 cases 
were included in the intervention group, while 38 cases were included in the control 
group. Data showed that patients treated with RFA would cause higher costs at the 
time point of treatment compared to others (€ 2,068 vs. € 1,490; n.s.). However, during 
the 2-year follow-up period, the overall costs for controls were € 1,254 higher than 
that for cases (€ 4,561 vs. € 5,815; n.s.). The main cost drivers were medication costs 
from the outpatient setting (€ 495 vs. € 1,228; n.s.), outpatient physician consultations 
(€ 1,355 vs. € 1,683; n.s.) and inpatient treatments (€ 2,025 vs. € 2,726; n.s.). The sav-
ings during follow-up compensated the higher costs in the beginning, so that each 
patient treated with RFA caused € 676 less costs than patients treated with other 
endometrial ablation techniques. ConClusions: Although having small sample 
sizes, the results showed that patients treated with RFA cause less overall costs 
within 2 years. Main reasons for differences in costs were medications prescribed in 
the outpatient setting, inpatient treatments and outpatient physician consultations.
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objeCtives: Non-invasive prenatal testing (NIPT) is a method that is based on small 
portions of cell-free fetal DNA (cffDNA) that is present in the woman’s blood during 
pregnancy. Analysis of cffDNA in a blood sample can be used for different types of 
prenatal diagnosis. The use of NIPT to detect trisomies has developed rapidly over 
the past four years. The aim of this study was to examine the costs and cost effec-
tiveness of NIPT to detect trisomy 21 (T21, Down’s syndrome) in Sweden. Methods: 
The procedures of a cost-analysis and a cost-effectiveness analysis were followed 
using true number of detected T21 as outcome. The main comparator was the 1st 
trimester combined test (nuchal translucency (NT) in combination with levels of 
free-β -hCG and PAPP-A). For the estimation of sensitivity and specificity of T21 
using NIPT, a meta-analysis using data from 32 studies were used. Calculations 
were performed for 10 000 pregnancies with an average age of the women at 30 
years, tested in week 12, and with an average risk of having trisomy 21 (1:526). The 
price of NIPT was set to € 542 (no price is yet available in Sweden). Costs and qual-
ity of life related to living with T21 were not included. Results: Using NIPT as a 
first line procedure increases the costs from about € 2 M to more than € 5 M and its 
cost-effectiveness ratio become about € 2 M per extra true detected T21 compared to 
the combined test. Using NIPT as a second line procedure (following the combined 
test with a cut-off risk at 1:200) leads to reduced costs and fewer procedure-related 
miscarriages, but with 0.04 fewer T21 detected. ConClusions: The use of NIPT to 
test for T21 increases the number of detected T21. It is not possible to clarify what 
testing strategy (if any) that would be considered cost-effective.
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objeCtives: Procalcitonin (PCT) is a specific marker for differentiating bacterial 
from non-infective causes of inflammation that was recently proven cost-effective 
complications was 1243 euros in the single-use group and 2067 euros in the re-use 
group. ConClusions: Almost two thirds of the additional catheter cost associated 
with the single-use strategy in comparison to re-using catheters was offset from 
savings due to fewer complications. The decrease in patient suffering from fewer 
complications would also add to the benefits of single-use strategy.
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objeCtives: Many patients with overactive bladder (OAB) treated with anticho-
linergic medications (AM) continue to experience urinary symptoms; some may 
be candidates for specialized treatment including sacral neuromodulation (SNM). 
This analysis determined AM costs in OAB patients who were enrolled in the InSite 
study. Methods: Subjects who failed > 1 AM and were candidates for SNM were 
enrolled in a prospective, multicenter trial. For patients receiving SNM, AM use was 
not permitted during the first 6 months. Thereafter patients could use medication 
if needed. Patient-reported AM cost at 12 months post-implant, based on an eco-
nomic impact questionnaire inquiring about AM cost over the past 2 months, was 
compared to baseline. AM cost at baseline and 6 months for a separate cohort ran-
domized to standard medical therapy (SMT) is included for comparison. Results: 
Of 231 SNM patients, 207 had baseline and follow-up data, of which, 74 (35.7%) 
reported baseline AM costs > $0. Of 74, 4 (5.4%) reported AM costs at 12 months. Of 
133 patients with $0 baseline cost, five (3.8%) reported AM cost > $0 at 12 months. 
Of the 207, the average cost/patient over a 2-month period was $178 at baseline and 
$14 at 12 months post-implant. Of 75 SMT patients, 68 had baseline and follow-up 
data, of which, 28 (41.2%) reported baseline AM costs > $0. Of 28, 19 (67.9%) reported 
AM costs at 6 months. Of 40 patients with $0 baseline cost, 11 (27.5%) reported AM 
cost > $0 at 6 months. Of the 68, the average cost/patient over a 2-month period was 
$176 at baseline and $218 at 6 months. ConClusions: For patients receiving SNM, 
the average AM cost/patient markedly decreased by 92.1% at 12 months. Reductions 
were not seen for patients receiving SMT, where the average AM cost per patient 
increased by 23.9% at 6 months.
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objeCtives: Clinical use of next-generation sequencing(NGS) techniques has tre-
mendously risen. This is the result of technological advancements and simultane-
ously decreasing sequencing costs. Although the long-awaited $1,000 genome seems 
near, a clear and complete overview of the costs of NGS techniques is currently 
missing. Moreover, it is still unclear how NGS technologies should be used in clini-
cal practice. This study assesses the costs associated with three NGS technologies: 
Targeted gene panels(TGP), whole exome sequencing(WES), and whole genome 
sequencing(WGS). Additionally, a framework is constructed, balancing costs and 
diagnostic yield. Methods: The total costs of TGP, WES and WGS were calculated 
at the Radboud university medical center. TGP, WES and WGS can be used in various 
diagnostic workflows in which one test could serve as a pre-test to another. A deci-
sion framework was constructed that takes into account the costs and diagnostic 
yields of various workflows, informing on which workflow is most favourable at 
what diagnostic yields. PRELIMINARY. Results: The per-sample costs of TGP (€ 500) 
are two and five times lower than per-sample costs of WES (€ 1,000) and WGS (€ 2,600), 
respectively. Nevertheless, using it as a pre-test for WES or WGS is only cost-saving 
if its’ diagnostic yield exceeds 60 or 20%, respectively. Using WES as a pre-test for 
WGS saves costs when its’ diagnostic yield exceeds 40%. ConClusions: This study 
is the first complete overview of the costs of NGS technologies. Although it is often 
claimed that the $1,000 genome is near, our study shows that taking into account 
all direct medical costs associated with NGS, the costs of WGS are still consider-
ably higher. The per-sample costs of TGP, WES and WGS are dependent on several 
assumptions, such as annual throughput and coverage. To assure transferability 
of our results, we constructed a flexible framework in which these assumptions 
can be adapted.
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objeCtives: Deep Brain Stimulation (DBS) for the treatment of advanced 
Parkinson’s Disease (aPD) is a therapy supported with high-level clinical evidence, 
but to date its cost-effectiveness in the Swedish health care system has not been 
fully evaluated. Our objective was to evaluate the cost-effectiveness of DBS in aPD 
compared with best medical therapy (BMT), Duodopa and Apomorphine from the 
perspective of the Swedish payer. Methods: A Markov model previously used to 
model the cost-effectiveness of DBS in the UK setting was updated and adapted to 
the Swedish setting, using local cost data, resource use estimates, anti-Parkinson 
drug protocols, hospital price lists, Swedish mortality data and expert opinion. 
Efficacy data were taken from an RCT of DBS versus BMT, combined with long-term 
